Réactifs et instruments pour l'immunologie, la biologie cellulaire et la biologie moléculaire.
 
> Baricitinib [1187594-09-7]

Baricitinib [1187594-09-7]

Imprimer Imprimer
Identifiez-vous

Référence 10-3893-25mg

Conditionnement : 25mg

Marque : Focus Biomolecules

Demander plus d'informations

Contactez votre distributeur local :


Téléphone : +1 850 650 7790
Baricitinib [1187594-09-7]

Baricitinib | JAK 1/2 inhibitor

CAS:
1187594-09-7
Catalog Number:
10-3893
Activity:
JAK 1/2 inhibitor
Chemical Name:
1-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azetidine-acetonitrile
Alternate Name:
INCB028050; LY3009104
Molecular Weight:
371.42
Molecular Formula:
C16H17N7O2S
Solubility:
Soluble in DMSO (up to 30 mg/ml) or in DMF (up to 50 mg/ml).
Physical Properties:
White or off-white solid
Purity:
98% by HPLC
NMR (Conforms)
Storage Temperature:
-20°C
Stability:
Stable for 2 years from date of purchase as supplied. Solutions in DMSO or DMF may be stored at -20°C for up to 3 months.
Shipping Code:
RT

Available Options

Size: Quantity 
5 mg$48.00
25 mg$100.00
Request Quote / Bulk / Custom Size
Product Inquiry

Baricitinib (1187594-09-7), approved by the FDA for two inflammatory disorders, rheumatoid arthritis and alopecia areata, selectively inhibits Janus kinase 1 (IC50 = 5.9 nM) and 2 (5.7 nM), over 3 (0.56 µM).1 It thereby blocks JAK/STAT signaling, reducing cytokine release and suppressing the innate and adaptive immune systems.1,2 Was recently shown to significantly improve COVID-19 symptoms in a preliminary human trial, presumably through suppression of the cytokine release syndrome (“cytokine storm”) induced by SARS-CoV-2 infection.3

References/Citations:

1) Fridman et al. (2010), Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050; J. Immunol. Biol., 184 5298
2) Kubo et al. (2018), Janus Kinase Inhibitor Baricitinib Modulates Human Innate and Adaptive Immune System; Front. Immunol., 9 1510
3) Cantini et al. (2020), Baricitinib Therapy in COVID-19: A Pilot Study on Safety and Clinical Impact; J. Infect., 81 318

CAS:
1187594-09-7
Catalog Number:
10-3893
Activity:
JAK 1/2 inhibitor
Chemical Name:
1-(Ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]-3-azetidine-acetonitrile
Alternate Name:
INCB028050; LY3009104
Molecular Weight:
371.42
Molecular Formula:
C16H17N7O2S
Solubility:
Soluble in DMSO (up to 30 mg/ml) or in DMF (up to 50 mg/ml).
Physical Properties:
White or off-white solid
Purity:
98% by HPLC
NMR (Conforms)
Storage Temperature:
-20°C
Stability:
Stable for 2 years from date of purchase as supplied. Solutions in DMSO or DMF may be stored at -20°C for up to 3 months.
Shipping Code:
RT

Safety Data Sheet:

N/A

Product Data Sheet:

Download Product Data Sheet

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a restocking/refund fee

Baricitinib (1187594-09-7), approved by the FDA for two inflammatory disorders, rheumatoid arthritis and alopecia areata, selectively inhibits Janus kinase 1 (IC50 = 5.9 nM) and 2 (5.7 nM), over 3 (0.56 µM).1 It thereby blocks JAK/STAT signaling, reducing cytokine release and suppressing the innate and adaptive immune systems.1,2 Was recently shown to significantly improve COVID-19 symptoms in a preliminary human trial, presumably through suppression of the cytokine release syndrome (“cytokine storm”) induced by SARS-CoV-2 infection.3

References/Citations:

1) Fridman et al. (2010), Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050; J. Immunol. Biol., 184 5298
2) Kubo et al. (2018), Janus Kinase Inhibitor Baricitinib Modulates Human Innate and Adaptive Immune System; Front. Immunol., 9 1510
3) Cantini et al. (2020), Baricitinib Therapy in COVID-19: A Pilot Study on Safety and Clinical Impact; J. Infect., 81 318